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Abstract
In this third article we describe the pharmacological interactions resulting from the use of anti-microbial agents. Al-
though the antimicrobials prescribed in odontology are generally safe they can produce interactions with other medi-
caments which can give rise to serious adverse reactions which are well documented in clinical studies. Antibiotics 
with grave and dangerous life threatening consequences are erythromycin, clarithromycin and metronidazol and the 
anti-fungal agents are ketoconazol and itraconazol. Regarding the capacity of the anti-microbials to reduce the efficacy 
of oral anti-contraceptives the clinical studies to date are inconclusive, however, it would be prudent for the oral cavity 
specialist to point out the risk of a possible interaction. Therefore the specialist should be aware of possible interactions 
as a consequence of administering an antibiotic together with other medicaments the patient may be taking.
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Introduction
The duration of therapy with antimicrobial agents in odon-
tology (except in prophylaxis of endocarditis and articular 
prothesis) is generally more prolonged than other types of 
medicaments used in odontology. Therefore this fact in-
creases the risk of adverse pharmacological interactions in 
comparison with other classes of medicaments. The aim of 
this third article is to describe the pharmacological inter-
actions which have major clinical repercussions resulting 
from antibiotics prescribed in odontology such as clari-
thromycin, erythromycin, ciprofloxacin, metronidazol and 
antifungal azolics like ketoconazol and itraconazol.
Interaction of erythromycin, clarithromycin, 
antifungal azolics and metronidazol with medi-
cament substrates of CYP 3A4
In the first article of this series we described the mecha-
nism of the pharmacological interaction at the pharmak-
inetic level in relation to metabolism. The enzymatic 
systems involved in the bio-transformation of the ma-
jority of the medicaments are located principally in the 
smooth endoplasmic reticulum of the liver, which con-
tains an important group of oxidative enzymes called 
monooxidases or oxidases of mixed function. This is 
the location of the cytochrome family of which the P450 
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cytochrome system is prominent (1). The following is 
the nomenclature of these enzymes: CYP followed by 
the number representing the family of iso-enzymes, fol-
lowed by a letter representing the sub-family and finally 
another number representing the individual gene (e.g. 
CYP3A4).  There are more than 30 P450 cytochrome 
isoenzymes, the most important of which are CYP1A2, 
CYP2C9, CYP2D6, CYP2E1 and CYP3A4 (2). The 
CYP3A4 isoform is the most abundant cytochrome fam-
ily in the liver and human intestine. In pharmacological 
interactions an induction or enzymatic inhibition can 
be produced at the metabolic level. During enzymatic 
inhibition the precipitating medicament inhibits the 
metabolism of the medicament objective increasing its 
plasma concentration and therefore a risk of toxicity. In 
this case the manifestations are much more immediate 
than in enzymatic induction (3). The macrolide antibi-
otics erythromycin and clarithromycin are potent irre-
versible inhibitors of the CYP3A4 and CYP1A2 isoen-
zymes which can significantly increase concentrations 
in blood and toxicity of other medicaments (substrates) 
which use this system of detoxification (Table 1) (4). 
Normally for the interaction to appear the CYP3A4 
inhibitor has to be taken for at least three to five days 
beforehand although there are published cases where 
an interaction has been seen on the first day of tak-
ing the medication (5). While the macrolide antibiotics 
erythromycin and clarithromycin are potent inhibitors 
of CYP3A4, azithromycin is not (there are few interac-
tions associated with azithromycin), which makes it a 
safe alternative in patients taking medicaments which 
could interact with the latter (6). This could be due to 
the chemical structure of azithromycin compared with 
erythromycin and clarithromycin. All the macrolides 
are composed of a macrocyclic lactone ring joined by 
glucoside bond to various deoxyazucar amines (7). They 
are classified according to the number of carbon atoms 
present in the lactone ring. Erythromycin and clarithro-
mycin have 14 carbons in the ring, while azithromycin 
is a molecule of 15 carbons. This additional carbon is 
responsible for impeding it joining to CYP3A4 (8).
They interact with the majority of medicament antago-
nists of calcium channels used for treating arterial hy-
pertension and arrhythmia, with anti convulsives (car-
bamazepine) (9), with inhibitors of the enzyme 3-hy-
droxy-3-methyl-glutaril-coenzyme A used for treating 
hypercholesterolemia like atorvastine, lovastine and 
sinvastine (with pravastine there is no interaction as it 
is not metabolised by CYP3A4). There are documented 
cases of rabdomyolisis (syndrome due to skeletal mus-
cle lesions) resulting from the association of sinvastine 
with fluconazol (10) (Table 1). Interactions have also 
been described with cyclosporin and tacrolimus, im-
munosuppressive medicaments used for maintenance of 
solid organ transplanted patients or in the treatment of 
autoimmune diseases (psoriasis, rheumatoid arthritis). 
Cotrimazol also raises the level of tacrolimus in renal 
transplanted patients. Opiate analgesics like alfentanil 
and inhibitors of protease (antiviral agents used for 
treating HIV and AIDS) like indinavir, nelfinavir, riton-
avir and saquinavir (11) are CYP3A4 substrates whose 
levels increase when ingested together with these inhib-
itors (4,12). When CYP3A4 antimicrobial inhibitors are 
administered with warfarin an increase of prothrombin 
time and INR with risk of bleeding has been observed 
(13).Terfenadine is a promedicament which undergoes 
almost complete metabolism by CYP3A4 in the intes-
tine and liver producing an active metabolite, fexofena-
dine which produces the desired antihistamine effect. 
Terfenadine is potentially cardiotoxic and if its metabo-
lism (via the isoenzyme CYP3A4) is altered it can accu-
mulate in the organism and produce serious cardiotoxic 
effects (5). Erythromycin, clarithromycin, ketoconazol 
and itraconazol give rise to an accumulation of initial 
terfenadine and its metabolite fexofenadine Electrocar-
diographic changes (prolongation of QT intervals) have 
also been observed (14). Azihtromycin (macrolide an-
tibiotic) does not have any interaction with terfenadine 
nor with astemizol (15). Cisapride is a medicament used 
in the treatment of esophagic-gastro reflux.  A possible 
consequence of the simultaneous ingestion of CYP3A4 
inhibitors (erythromycin, clarithromycin, metronidazol 
antifungal agents) with cisapride is grave ventricular 
arrhythmias. It is very important to be aware of this in-
teraction which is not as well known as those produced 
with antihistamines (5) (Table 1).
Regarding midazolam (benzodiazepine used as an oral 
sedative in odontology) it has to be taken into account 
that it is a CYP3A4 substrate which increases its blood 
level even with a single dose of benzodiazepine when 
associated with a CYP3A4 inhibitor which can result 
in a deep depression of the CNS (16). Ketoconazol and 
itraconazol have dramatic effects on these hypnotic 
sedatives increasing blood concentrations of oral mida-
zolam and triazolam 15 and 27 times respectively. An 
intense and prolonged psychomotor alteration, up to 17 
hours, accompanies these pharmakinetic changes (5). 
As described the structure of azihtromycin prevents 
this from altering the levels of midazolam. Fortunately, 
the benzodiazepines given orally, like midazolam and 
triazolam have very high therapeutic indices compared 
with other antianxiety-sedatory medicaments.
Interaction of metronidazol and fluconazol with 
CYP2C9 substrates
Metronizadol and the antifungal fluconazol also inhib-
it CYP2C9 giving rise to an accumulation of various 
substrates of this isoenzyme. The CYP2C9 substrates 
are anticoagulants (warfarin), anticonvulsives (fenitoin, 
carbamazepine) (17) ARAII (losartan, ibresartan), hy-
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perglucemics (glipizide, gliburide, tolbutamide) and 
NSAIs (ibuprofen, naproxen, diclophen) (4,5,12) (Table 
2). The more interesting interaction from the point of 
view of clinical dentistry is that of metronidazol with 
warfarin which significantly increases the blood levels 
and median life of these anticoagulants therefore giving 
rise to a higher tendency for hemorrhagia (18). To this 
we have to add the capacity metronidazol has of inhib-
iting the CYP2C9 enzyme which metabolises fenitoin 
producing an accumulation of this antiepilectic agent 
resulting in an increased risk of somnolence, confusion, 
diplopia, ataxia and nistagmo. The antifungal fluconazol 
also inhibits the activity of CYP2C9 which can produce 
the same interactions with respect to warfarin and feni-
toin (19,20). An increase has also been observed in the 
concentrations of carbamazepine in patients with epi-
lepsy undergoing treatment with ketoconazol. Nistatin 
can be used as an alternative for oral fungal infections 
in patients not immunocompromised. However, realistic 
therapeutic alternatives do not exist for azolic antifun-
gal treatment (12). As metronidazole is generally used 
for the anaerobic component of oral infections together 
with penicillin which treats the aerobic, clindamycin 
can be used as an alternative for these mixed infections. 
It is advisable that before prescribing metronidazol 
or fluconazol to dental patients undergoing long-term 
treatment with warfarin and fenitoin to consult a spe-
cialist in these medicaments (4,15). Another potential 
interaction, where the clinical significance is unclear, 
is the capacity of fluconazol to diminish the metabolic 
activity of CYP2C9 of the promedicaments losartan (an 
ARAII, medicament reference of this group) of its ac-
tive metabolite E-3174, potentially diminishing its anti-
hypertensive action (21) (Table 2).
Interaction of ciprofloxacin and erythromycin 
with CYP1A2 substrates
The antibiotics, ciprofloxacin and erythromycin are in-
hibitors of the CYP1A2 isoenzyme, of P450 cytochrome 
which can reduce biotransformation and increase blood 
Medicament substrates of CYP3A4 (interac-
tion objective) Potential Interaction
Antihistamines H1: cisapride, terfenadine Accumulation of substrate leading QT intervals and ven-
tricular arrhythmia
Hypocholesterics: atorvastatine, cerivastatine 
lovastatine, simvastatine
Accumulation of substrate leading to diffuse myalgia, rab-
domyolisis and renal failure blocking the renal tubule sys-
tem by skeleto-muscular degradation products
Calcium antagonists: felodipine, nifedipine, 
amlodipine, verapamil, diltiazem
Substrate accumulation leading to increased hypersensi-
tivity producing sever hypotension and edema
Immunosuppresors: cyclosporine, tacrolimus Substrate accumulation leading to excessive Immunode-
pression and nephrotoxicity
Anticoagulants: warfarina Substrate accumulation, increase of prothrombin and INR* 
time, increased bleeding risk
Anitepileptics: carbamazepine Substrate accumulation, ataxia risk, vertigo, somnolence 
and confusion
Antivirals: indinavir, nelfinavir, ritonavir, 
saquinavir
Substrate accumulation, cardiac altercation risk
Opiate analgesics: alfentanile Substrate accumulation, respiratory depression risk
Benzodiazepines: alprazolam, diazepam, 
midazolam, triazolam
substrate accumulation, excessive and prolonged sedation, 
increased air obstruction risk in children
Table 1. Inhibition of P450 CYP3A4 cytochrome enzyme by macrolide antibiotics (erythromycin, clarithromycin), azolic 
antifungal agents (ketoconazole, fluconazole) and metronidazole.Adverse reactions that can result from the inhibition of 
CYP3A4 which metabolises their medicament substrates.
*INR: International Normalized Ratio
Table 2. Inhibition of CYP1A2 and 2C enzymes of P450 cyto-
chrome by antibiotics, antifungal and antiinfection agents. Inhibi-
tion of CYP1A2 and 2C increases medicament effects with which 
they react.
CYTO-
CHROME INHIBITOR
MEDICAMENT 
OBJECTIVE OF THE 
INTERACTION
1A2
Macrolide 
antibiotics
 Erythromicin
Clarithromycin
           Teofiline
     Antidepressors
 Amitriptyline
Clomipramine
 Fluvoxamine
  Imipramine
     Antipsychotics
       Haloperidol
        Clozapine
2C
Azolics anti-
fungals
Ketoconazol
Fluconazol
Metronidazol
Anticonvulsives
       Fenitoin
Anticoagulant
            Warfarin
E126
Med Oral Patol Oral Cir Bucal. 2009 Mar 1;14 (3):E123-8.                                                                                                                                        Pharmacological interactions of anti-microbial 
levels of medicaments which are substrates of CYP1A2 
such a tacrine, antihistamines (teofilin) antidepressors 
(fluvoxamine, imipramine) and anti psychotics (ha-
loperidol, clozapine) (1,4) (Table 2). Tacrine, a medi-
cament used for treating Alzheimer, is an inhibitor of 
acetylcholinesterase, leading to a rise in the concentra-
tions of acetylcholine. The high levels of tacrine result-
ing from excessive activity of muscarine and nicotine 
receptors with consequent excess saliva, tears, sweat-
ing, gastrointestinal hypermobility, bradicardia, miosis, 
muscular cramp and excitation of the CNS (22). The 
accumulation of teofiline implicates excessive blockage 
of receptors of phosphodiesterase and adenosine which 
gives rise to tachycardia and other disrhythmias, trem-
ors and convulsions (1,4,23,). The potential interaction 
produced with fluvoxamine and imipramine antidepres-
sors results in an excess of anticholinergic activity and 
alpha 1 blockage, clinically leading to xerostomia, in-
crease of intraocular pressure, tachycardia and disrhyth-
mias, sedation, confusion, constipation and orthostatic 
hypertension. Haloperidol and clozapine, substrates of 
CYP1A2 increase their concentration which can lead to 
an excessive anticholinergic, antidopaminergic effect 
and alpha 1 blockage which can provoke xerostomia, 
sedation, tachycardia, constipation, extrapiramidals 
and orthostatic hypotension (4,12).
Interaction of metronidazol with alcohol and lithium
Metronidazol can interact with both alcohol and lithium. 
These two interactions are of special interest above all 
because of the toxicity that can result with lithium.
Metronidazol with alcohol
Metronidazol, just like disulfiram (antabus effect) inhi-
bits the activity of the enzyme acetaldehyde dehydro-
genase leading to an accumulation of acetaldehyde in 
patients consuming alcohol (24). The clinical ability of 
metronidazol to produce similar reactions to disulfiram 
in patients consuming alcohol is based on various stu-
dies showing an incidence in 2% of the population stu-
died. The reaction leads to nauseas, cardiac palpitations 
and headache. The odontologist should warn the patients 
not to drink alcohol during metronidazol treatment for 
at least three days after the final treatment (2, 3,9,).
Metronidazol with lithium
Intoxications have been produced by lithiums a conse-
quence of metronizadol prescription. Lithium is used 
for treating manic-depressive pathologies (bipolar), and 
more frequently during the maniac phase but always 
under strict control and monitoring because of its low 
therapeutic index. It is important to be aware of signs 
of acute intoxication by lithium: lethargy, muscle weak-
ness, and hand tremors. The more serious intoxications 
include confusion, nistagmo, and ataxia. Coma and cir-
culatory collapse are more grave processes which can 
result from this toxicity (3,5). This grave interaction 
has been demonstrated and is potentially life threate-
ning. Because of its low therapeutic index high levels 
of lithium can produce an altercation of renal function, 
sometimes in the form of insipid diabetes.
Interaction of tetracyclines and quinolines with 
cations 
There are two groups of antibiotics, tetracyclines and 
quinolines, which form chelates with divalent and tri-
valent cations found in the diet, antiacids and vitamins. 
These chelates are insoluble and cannot be absorbed 
through the gastrointestinal tract mucosa and the blood 
stream and so are excreted. Consequently the antibiotic 
or cation has no activity.
Tetracyclines with cations
Antibiotics of the tetracycline group like tetracycline, 
doxycycline and minocycline form insoluble complexes 
called chelates when administered, via the same route, 
at the same time or almost the same time as divalent ca-
tions (1,5). Therefore the bivalent cations like calcium, 
magnesium, bismuth, iron, zinc and aluminium (found 
daily in diets, in antiacid products and vitamins) alter 
the absorption of tetracycline molecules by the gastro-
intestinal tract (1). If doxycycline is taken with milk or 
antiacids it will form a chelate and the calcium and doxy-
cycline will not be absorbed in the gastrointestinal tract 
and will be excreted in the faeces (12). A diminution of 
around 20% of serum concentrations of tetracycline in 
the presence of these cations has been observed. This is 
a known and well documented interaction. In these cases 
it would be prudent to avoid simultaneous ingestion of 
tetracycline and multicationic products by spacing out 
both these ingestions (5,15,25,). Tetracycline antibiotics 
should be taken two hours before or after food, nutrition, 
mineral supplements or antiacids containing calcium, 
magnesium, or divalent iron. This is of interest in chil-
dren because of the importance of calcium for growth 
and development of bones and teeth, and in women to 
prevent osteoporosis especially as many foodstuffs are 
enriched with calcium thus giving rise to this potential 
pharmaco-alimentation interaction (12).
Quinolines with cations
The antibiotics of this group of quinolines, like cypro-
floxacine also form chelates with trivalent cations 
like iron and zinc. In studies on hospitalised patients 
receiving medication via the enteric tube, it has been 
observed that when the quinoline antibiotic is adminis-
tered in this way the concentrations reaching the blood 
stream are very low or null. Accordingly the adminis-
tration of quinoline antibiotics should be separated from 
the ingestion of supplements containing zinc or iron by 
at least two hours.
Interaction of erythromycin, clarithromycin and azi-
thromycin with digoxin
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Digoxin is absorbed favourably when administered 
orally (approximately 75%). Clarithromycin and eryth-
romycin can produce toxicity by digitalics in patients 
with a rapid increase of blood levels of digoxin (3,5). 
Approximately 10% of the population has intestinal 
bacteria (Eubacterium lentum), which metabolises a 
large portion of digoxin diminishing its bio-availability 
and consequently need larger doses for maintenance 
during treatment (1). In these patients clarithromycin, 
erythromycin and azithromycin can inhibit the growth 
of these intestinal bacteria by sufficiently increasing the 
levels of digoxin (4). As digoxin has a very low thera-
peutic index prescription of these antibiotics should be 
avoided in patients taking digoxin.
Interaction of antibiotics with oral anticoagulants
Generally, antibiotics alter the normal intestinal flora. 
This flora is important in preventing overgrowth of op-
portunistic infections in the gastrointestinal tract and is 
essential for the production and/or absorption of some 
nutrients, vitamins and medicaments. When this flo-
ra diminishes gastrointestinal discomforts can appear 
(nauseas, vomiting) as well as lesser ability of produ-
cing vitamin K and to recycle and absorb some hormo-
nes like estrogens at the enterohepatic level. Intake of 
antibiotics supposes lesser absorption of vitamin K and 
consequently a decrease in the production of vitamin K 
dependent coagulation factors, VII, IX, X and proba-
bly V (12). Therefore there is a greater risk of bleeding 
which is clinically important in patients taking warfarin 
over prolonged periods (20, 26). Warfarin and dicuma-
rol are competitive antagonists for vitamin K dependent 
coagulation factors and have a low therapeutic index 
(1). The administration of other medicaments, like wide 
spectrum antibiotics, can raise this antagonistic acti-
vity which in turn produces a serious increase in the 
blood and a threat for the patients’ life (12). As reported 
previously antimicrobial inhibitors of CYP3A4, when 
administered to patients taking warfarin there is an in-
crease of INR and major risk of bleeding. It is suggested 
that wide spectrum antibiotics like tetracycline, amoxi-
cillin, ampicillin and clarithromycin can reduce the en-
dogenic levels of vitamin K and raise the effects of oral 
anticoagulants by altering the normal intestinal flora 
which vitamin K produces (1). Apparently the ability of 
these antibiotics to increase the anticoagulatory activity 
is relatively rare and unpredictable (5). When the longer 
the patient is undergoing treatment with antibiotic the 
greater the risk of bleeding. Wide spectrum antibiotics 
can be prescribed  to patients taking warfarin (patients 
with normal ingestion of vitamin K) but they should be 
advised to look for signs of bleeding and consult the 
doctor immediately (5,12,18).
Interaction of antibiotics with oral contraceptives
One of the widely discussed interactions is the ability of 
certain antibiotics to reduce blood concentrations and 
the efficacy of oral contraceptives.  The two components 
of contraceptive pills, semi-synthetic estrogens (estra-
diol ethinil or mestranol) and semi-synthetic progestro-
nes (progestines) are CYP3A4 substrates (1,3,5,). It has 
been shown that rifampicin (aminoglucosides used for 
tuberculosis treatment) and its analog rifabutine signifi-
cantly reduces blood levels of the contraceptive as they 
are potent inducers of the CYP3A4 isoform. Rifamycin 
is a potent inductor of the P450 hepatic cytochrome, and 
increases the metabolism of many medicaments inclu-
ding oral contraceptives (1). However, none of the an-
tibiotics used in odontology are inductors of CYP3A4 
and moreover, erythromycin and clarithromycin are 
inhibitors of this enzyme which would raise the levels 
of the contraceptive (27,28). Cases have been published 
of contraceptive failure after antibiotic therapy with pe-
nicillin, tetracylines, metronizadol, erythromycin and 
Fig. 1. Pharmacological bases of antibiotics interaction with oral contraceptives.
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cefalosporins (29). However, clinical studies have not 
shown any significant reduction clinically or statisti-
cally in blood levels of contraceptives and neither its 
efficacy (5,15). The most accepted theory to explain the 
mechanism of sporadic cases of contraceptive failures 
is based on the ability of the antibiotics to inhibit the en-
terohepatic recirculation of the estrogen component of 
the contraceptives (3,30) (Fig.1). The intestinal bacteria 
hydrolyse glucuronic acid of the sulphate groups (SO4) 
of the estrogen component, liberating the liposoluble 
and active part that can be reabsorbed by the intesti-
ne and pass on to the blood circulation. In the presence 
of antibiotics the enteric bacteria are markedly reduced 
which produce a reduction of the reabsorbed estrogen 
which is then excreted (3). The levels of estrogen fall, 
restoring the capacity to ovulate. In theory this entero-
hepatic recirculation can be inhibited by antibiotics that 
destroy the bacteria of the colon implicated in the pro-
cess of deconjugation (Fig.1). The failure of oral contra-
ceptives in women who simultaneously take antibiotics 
could indicate, or form part of, the normal proportion of 
failures of these medicaments, or that it is a relatively 
rare interaction that cannot be detected in clinical trials. 
However, it would be prudent for the dentist to warn the 
women undergoing treatment with contraceptives of the 
possible interaction when prescribing antibiotics. Also 
it would be advisable to recommend other methods of 
contraception (while continuing oral contraceptives) 
during antibiotic therapy for at least one week after the 
last dose of antibiotic (30).
Conclusions
The antibiotics the odontologist prescribes that present 
major risk of pharmacological interaction with serious 
and dangerous life threatening adverse reactions are 
erythromycin, clarithromycin, ciprofloxacin and metro-
nidazol and also the anti fungal azolics, ketoconazole 
and itraconazole. This is because these antimicrobial 
agents are potent inhibitors of various P450 cytochrome 
isoenzymes. Consequently there is a major risk of po-
tential pharmacological interactions with medicaments 
which are substrates of these isoenzymes and could lead 
to an increase of the substrate in the blood stream. Subs-
trates of medicaments which have low therapeutic index 
have special clinical repercussions because small varia-
tions in their concentration could produce toxic effects.
Thus the importance of suspecting the appearance of 
serious pharmacological interactions when prescribing 
antimicrobial agents in odontological practice.
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